EMA Confirms Recommendation Of Synchron Suspensions
But Finds Alternative Data To Support Marketing Authorizations For Eight Medicines
Following a review of an earlier decision, the European Medicines Agency has confirmed its recommendation to suspend marketing authorizations for dozens of medicines with bioequivalence studies conducted by Synchron Research Services. However, eight products have been spared after alternative supporting data was identified.
